UniQure Targets FDA Filing for Huntington’s Gene Therapy

After a pivotal consultation with federal regulators, biotech firm UniQure has secured a path toward market authorization for its investigational Huntington’s disease treatment, AMT-130. The FDA confirmed that three-year data from existing clinical trials will suffice as the foundational evidence required to initiate a Biologics License Application.

Today, 16:00· Money Talk· 775 reads

UniQure Targets FDA Filing for Huntington’s Gene Therapy

The company intends to submit its formal application for the gene therapy in the third quarter of this year. While the three-year analysis serves as the primary support for this filing, the FDA has requested a collaborative framework for a subsequent confirmatory study to reinforce the clinical findings.

UniQure leadership stated they are prioritizing the design of this secondary study to ensure it aligns with agency expectations. By moving forward with the current data set, the company aims to expedite the regulatory process for a condition that currently lacks effective disease-modifying options.

UniQure Targets FDA Filing for Huntington’s Gene Therapy

Comments (0)